INTRODUCTION TO



PATIENT REPORTED OUTCOMES





Dagmara Kulis EORTC



Elizabeth Vroom Duchenne Parent Project





Mariangela Pellegrini ERN EuroBloodnet



Gavin McDonough <mark>Orphanet</mark>



Céline Desvignes-Gleizes MAPI Research Trust European Organisation for Research and Treatment of Cancer (EORTC)

Duchenne Parent Project

(15min break)

European Rare Disease Research Coordination and Support Action consortium (ERICA)

Final Q&A



Agenda



EURORDIS MASTERCLASS

Dagmara Kuliś Quality of Life Department European Organisation for Research and Treatment of Cancer







PRO

Patient-reported outcome

An outcome reported directly by patients themselves and not interpreted by an observer

PROM

Patient-reported outcome measure Tool used to assess a PRO



A need to assess QOL (1)

According to the World Health Organization (WHO), the main goals of cancer diagnosis and treatment programmes are to:

- CUIE Progression free survival (PFS)

considerably prolong the life of patients

Overall Survival (OS)

- ensure the best possible quality of life for cancer survivors.

Health-related quality of life (HRQOL)



A need to assess QOL (2)

- Clinicians, nurses, palliative care doctors, psycho-oncologists, researchers recognised the need to ask patients about their QOL in a standardised way.
- 1980: Formation of the EORTC Quality of Life Group network
- 1988: Published strategy on how to assess QOL
 - Core cancer questionnaire + disease-specific questionnaire
- 1993: Guidelines on how to develop quality of life questionnaires





An accepted working definition of HRQOL



But... how do you measure these various health-related quality of life aspects?



Physical functioning

- Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?
- 2. Do you have any trouble taking a long walk?
- 3. Do you have any trouble taking a short walk outside of the house?
- 4. Do you need to stay in bed or a chair during the day?
- 5. Do you need help with eating, dressing, washing yourself or using the toilet?
- Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?
- 2. Do you have any trouble taking a long walk?
- 3. Do you have any trouble taking a short walk outside of the house?
- 4. Do you need to stay in bed or a chair during the day?
- 5. Do you need help with eating, dressing, washing yourself or using the toilet?

Not at All	A Little	Quite a Bit	Very Much	
1	2	3	4	
1	2	3	4	
1	2	3	4	
	2	3	4	Л
	2	3	4	LL
Not at All	A Little	Quite a Bit	Very Much	
1	2	3	4	
1	2	3	4	
1	2	3	4	
1	2	3	4	I
	2	3	4	_

Person A

Person B

Between groups of people

Items taken from the EORTC QLQ-C30



Physical functioning

		Not at All	A Little	Quite a Bit	Very Much		
1.	Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?	1	2	3	4		At cancer
2.	Do you have any trouble taking a long walk?		2	3	4		diagnosis
3.	Do you have any trouble taking a short walk outside of the house?	1	2	3	4	П	
4.	Do you need to stay in bed or a chair during the day?		2	3	4	11	
5.	Do you need help with eating, dressing, washing yourself or using the toilet?		2	3	4		
		Not at All	A Little	Quite a Bit	Very Much		
1.	Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?	1	2	3	4		Month 3 on
2.	Do you have any trouble taking a long walk?	1	2	3	4		treatment
3.	Do you have any trouble taking a <u>short</u> walk outside of the house?	1	2	3	4		
4.	Do you need to stay in bed or a chair during the day?	1	2	3	4		
5.	Do you need help with eating, dressing, washing yourself or using the toilet?		2	3	4	1 8.	
		Not at All	A Little	Quite a Bit	Very Much		
1.	Do you have any trouble doing strenuous activities, like carrying a heavy shopping bag or a suitcase?	1	2	3	4	1	
2.	Do you have any trouble taking a long walk?	1	2	3	4		At end of
3.	Do you have any trouble taking a short walk outside of the house?	1	2	3	4		treatment
4.	Do you need to stay in bed or a chair during the day?		2	3	4	П	
5.	Do you need help with eating, dressing, washing yourself or using the toilet?		2	3	4	ER	
							Across time

Items taken from the EORTC QLQ-C30





How to get a good PROM that measures what it is supposed to measure?



EORTC questionnaires



Symptom-specific module

Fatigue, Cachexia, CIPN...

Other

Communication, Information, Spiritual Well-Being...



Item Library

157 questionnaires, 1028 questions

Q search the item library...

Include custom questionnaires from the community





How it started

Login to the Item Bank - BETA Version - Microsoft Internet Explorer provided by EORTC		_ 181 ×
File Edit View Favorites Tools Help		10 A
↓ Back + → + 🙆 🛃 🙆 Search 📾 Favorites 🗇 Media 🧭 🛃 - 👍 📝 🛄 🕼		
Address 🔞 http://www.eortc.be/itembank/	- 260	Links ³
EORTC Quality of Life Group ITEM BANK		-
Version [1.0]		
The Item Bank is a database including all items from EORTC Quality of Life modules from Phase II to Phase IV. This program allows you to conduct a search on the various existing items. It provides information on item development, translations, bibliography, and essential details.	other	
To enter the database, please click here		
If you have any problem, please click on <u>help</u>		
Found a bug ? Click <u>here</u>		
a inte	rnet	20



Module development





Patient-centredness





Issues







Issues

1	employment
2	being judged
3	being a burden to others
4	social support from families and friends
5	social support from health care providers
6	sudden attacks of tiredness
7	mentally exhausted
8	physically exhausted
9	problems with weight gain
10	problems with weight loss
11	pain in the throat
12	discomfort in the neck
13	headaches

14	muscle pain
15	pain in the joints
16	bone pain
17	coughing
18	difficulty breathing
19	altered taste
20	appetite changes
21	chewing
22	problems with gum
23	problems with teeth
24	speech problems
25	hoarseness
26	voice changes



Issue \rightarrow Item







Very much



The future of cancer therapy

Q swallowing

Include custom questionnaires from the community





Translatability Assessment





Translation process





Pilot-testing

Pil	ot-Testing:	Sample of a (comple	patient response sheet ⁽¹⁾ ted by interviewer)	
Qu	estion number		Comments	
a.	Difficulty?	Yes		_
b,	Confusing?	Yes		_
c.	Difficult words?	Yes		_
d.	Upsetting?	Yes		_
e.	How would <u>you</u> ask	this question?		_



Results – changes





The future of cancer therapy

Initial psychometric testing and changes





Field testing





Can I use the Item Library to develop a PROM in an easier/faster way?



@EORTC







157 questionnaires, 1028 questions

Search the item library...

Include custom questionnaires from the community





Official questionnaires		Custom questionnaires	Item classification
Standard classificatio	CTCAE classification		
+ Cardiac disorders	(6)		
+ Ear and labyrinth	disorders (5)		
+ Endocrine disorde	(E) 21		
+ Eye-disorders (85)			
+ Gastrointestinal d	sorders (308)		
+ General disorders	and administration site conditions (320)		
+ Immune system o	isorders (2)		
+ Infections and infe	stations (13)		
+ Injury, poisoning a	nd procedural complications (24)		
+ Investigations (33	1		
+ Metabolism and n	utrition disorders (18)		
+ Musculoskeletal #	nd connective tissue disorders (101)		
+ Nervous system o	isorders (286)		
+ Not classified (40	si 💼		
+ Psychiatric disord	ers (109)		
+ Rehal and unnary	disorders (30)		
+ Reproductive syst	em and breast disorders (93)		
+ Respiratory, thora	cic and mediastinal disorders (118)		
+ Skin and subcutar	eous tissue disorders (75)		
+ Surgical and medi	cal procedures (8)		
+ Vascular disorder	(11)		



Item list



Items from H&N43



Policy Review

Recommendations on the use of item libraries for patientreported outcome measurement in oncology trials: findings from an international, multidisciplinary working group



Claire Piccinin, Ethan Basch, Vishal Bhatnagar, Melanie Calvert, Alicyn Campbell, David Cella, Charles S Cleeland, Corneel Coens, Anne-Sophie Darlington, Amylou C Dueck, Mogens Groenvold, Ralf Herold, Bellinda L King-Kallimanis, Paul G Kluetz, Dagmara Kuliś, Daniel O'Connor, Kathy Oliver, Madeline Pe, Bryce B Reeve, Jaap C Reijneveld, Xin Shelley Wang, Andrew Bottomley

Lancet Oncol 2023; 24: e86-95



Thank you!





European Rare Disease Research Coordination and Support Action

EURORDIS MASTERCLASS

22nd May 2023

By ERICA WP3 - Patient-Centered Research in Rare Diseases

Mar Mañú Pereira, Ana Rath, Mariangela Pellegrini, Céline Desvignes-Gleizes, Gavin McDonough, Caterina Lucano, Benoit Arnould







Network Herostological Disectory (1911 havellowing)



Presenters







Céline Desvignes-Gleizes

Patient-Centred Outcomes specialist, Mapi Research Trust

Mariangela Pellegrini,

Educational and patients project manager, ERN-EuroBloodNet

Gavin McDonough

Disability Project Manager, Orphanet


Learning objectives

- Main objective: The impact of PROMs and the benefits of using them for advocacy
- Addressed questions:
 - Considerations before using PROMs
 - Why are PROMs so crucial for advocacy: Case study
 - ERICA project Tools to select adequate PROMs
 - How patient advocates can contribute?



European Rare Disease Research Coordination and Support Action

Considerations before using PROMs



Measuring what ? " One size doesn't fit all "







European Rare Disease Research Coordination and Support Action

Clarification of your PROMS-related objective is a prerequisite!





"Measuring What?": What do you need to hear from patients?







Assess quality of care, communication with health care staff and support medical decision-making





The context of use determines your PROMs selection





The context of use determines your PROMs selection

Example: Measure of depression

Screening:

- Hospital Anxiety and Depression Scale (HADS 14 items) : Quick completion time and immediate scoring
- **Assessment of programs** Measure of depression impact on QoL:
 - Quality of Life in Depression Scale (QLDS 34 items)
 - SF-36 (36 items)
 - Work Productivity & Activity Impairment Questionnaire (WPAI:D 6 items)

Assessment of mid-term outcomes of care on all patients from hospital:

- Motivation and Energy Inventory (MEI-SF - 18 items)

Assessment of intervention:

- Montgomery-Asberg Depression Rating Scale (MADRS – 10 items/signs and symptoms) 9



In a nutshell



10



Beyond PROMs validity, acceptance by patients and adoption by clinicians is critical





Criteria to consider to favor acceptance by patients and adoption by clinicians

- Feasible: PROM should be easy-to-use (e.g. NRS vs VAS)
- Actionable: PROM score should easily lead to decision-making and action (*eg* for *Diagnosis*: PHQ-9 thresholds 5, 10, 15 and 20 represented mild, moderate, moderately severe and severe depression, respectively)
- In-Context: PROM should be incorporated into the provider's routine process of care (*e.g. SF-36 good for research but complex scoring doesn't allow routine use*)
- Useful: PROM collection and processing should contribute to better healthcare





Importance of early patients' engagement in this process



European Rare Disease Research Coordination and Support Action

Why are PROMs so crucial for advocacy: example study



PROMs provide data and evidence on subjective needs and feelings











ENERCA Patient Questionnaire

"Patients' Needs and Expectations of Expert Centres in Haemoglobin Disorders"

This questionnaire should be answered by patients over 15 years old, or parents of patients under the age of 15. Please read the accompanying letter before answering. All information will be treated as confidential.

<u>Please note</u>: Section 3 (including 3a and 3b) is obligatory. Sections 1, 2 and 4 are optional, but it will be helpful it you complete them also.

Section 1 – About the patient (optional section)

Q1. Questionnaire completed by:

Patient		
Parent		
Other (e.g. relative, helper, patient association representa	Please specify: tive)	





Patient community expressing needs and burdens based on their experiences orally







Patient community expressing needs and burdens based on their experiences gathered in questionnaires that provide evidence













Patient feedback

« I spend a lot of time in day unit for receiving transfusion. I loose time from school or work »

Patient Need

The provision of transfusions in a timely manner and convenient for the patients hours

Data from the Patient Questionnaire

The majority of responders (63.84%) are transfused in **morning**

Of the patients transfused in the morning 30.7% are working full time, 13% are working part time and 21.6% are not working

Q18. Time of transfusion	Number of patients	Percentage	
Morning	256	63.84%	
Artemoom	11/	29.18%	
Evening	9	2.24%	
Overnight	10	2.49%	
Weekemd	8	1.99%	
Other (hospitalised for 3-5 days)	1	0.25%	



European Rare Disease Research Coordination and Support Action



Patient feedback

"My center doesn't guarantee me a good adherence to treatments. I experience a lot of pain"



Patient Need

Adherence to lifelong treatment requires support from the healthcare providers

|--|

Data from the Patient Questionnaire

27.77% of respondent are not treated in **expert centers**

31.45% were receiving Desferrioxamine monotherapy daily and 19.62% a combination of the subcutaneous drug and an oral chelator (Deferiprone)

More than half still had to adhere to difficult and painful treatments



→ Quantitative evidence provided by the questionnaire could support the shaping of Health Planning or Health Delivery centers

Determinate a way to provide clinical services as standard of care

Hospitals with transfusion centers open in the late afternoon

Formal recognition of disabilities, impairments and handicaps

> Having right to more days off from work



- ERICA project – Tools to select the adequate PROMs



ERICA Patient-Centric Research WP3 team

ERICA Objective: To facilitate the Europe-wide implementation of standardized

Patient-Centred Outcome Measures for rare diseases



Ana Rath Director Orphanet ERICA WP3 Co-lead



Mariangela Pellegrini

Educational & Patients Program manager -EuroBloodNet Assistance Publique - Hôpitaux de Paris (APHP)



Gavin McDonough Disability Project Manager Orphanet



Céline Desvignes-Gleizes Knowledge management and partnerships Mapi Research Trust / ICON



Mar Mañu Pereira

Principal Investigator Vall d'Hebron Institute of Research (VHIR) ERICA WP3 Co-lead





Reference Network for new ar low prevalence consider diseases



•

C ERICA

About • Work Packages • ERNs

Work Packages
 WP3 Patient-Centred Research - PROMa Repository

PROMs Repository

The ERICA Patient Reported Outcome Measures (PROMs) Repository is the first attempt to identify and centralize Clinical Assessment Outcomes questionnaires of relevance for rare diseases and constitutes a milestone in the Europe-wide standardization of Patient-Centered Outcome Measures (PCOMs) and PROMs for rare diseases. It has been made possible through the joint collaboration between Orphanet. Mapi Research Trust/ICON and ERN EuroBloodNet (VHIR, APHP), and the active contribution of ERNs and ePAGs. The methodology for the constitution and future evolution of the repository can be found in deliverable 3.1 (https://doi.org/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sci/10.1016/j.sc

The central repository is a dynamic and evolutive service and should be regarded as a centralized and standardized access gate to more in depth information contained in PROQOLID[™].

HI CONTRACTOR AND A CONTRACTOR A	111122									
PCOM/PROM Name ¹)					PCOM/PROM Type 21					
Target Age 4)					Domains 5					
Disease (OrphaName) 4					OrphaCode 7					
Group of Diseases 🎙					ERNs ^割					
O Legend										
Search Reset							Column	i Visibility 🔻	Column Res	et
٩								Showing	811 PCOMs/PR	31
PCOM/PROM Name	Туре	PROQULID~	Age	Domains	Oiscase (OrphaName)	OrphaCode	Group of Diseases	ERNs	PROQULID" Link	
Adult Sickle Call Quality of Life Measurement Information System® (ASCQ Me8)	PRO	₩ Full	Adult	Emotional impact sources Social functioning stress Pain source Suffrage stress Simp functioning source	Scite cell anomio	ORP54/232	Rare anemia	ERIX Excellionation	% .ici	12,000
EORTC - Chronic Myeloid Leukaemia (EORTC QLQ-CML24)	FRO	✓ Basic	Adult	Symptom Burden Impoct on Daily Life Impoct on Warry/Mood Brock Impoc	Non-Hadgkin lymphoma	ORPH4:547	Tumor of hematopoletic and lymphoid tissues	ERN EuroBloodNet ERN FædCan ERN EURACAN	€ <u>118</u>	

ERICA PROMs/PREMs repository

https://erica-rd.eu/work-packages/patient-centred-research/proms-

<u>repository/</u>

Repository v1.0 content:

- PROMs developed in Rare diseases (278)
- Generic Quality of life PROMs (5)
- PROMs measuring functional impacts (151)
- PROMs of interest for ERN (216)
- PROMs to assess health care management (161)

Repository v2.0 content: ObsRO



For complete information on PROMs

PROGOLID

PROMs Database

https://eprovide.mapi-trust.org/advanced-search?database=proqolid

Database content:

- Author information
- Conditions of use
- Translations
- Population of development
- PROMs review copy
- Information on development and validation of PROMs



2 ERN Pilots on PROMs implementation

ERN Transplantchild

 PETER Registry: Registry points for clinical data gathering (web)+ PROMS questionnaire (mobile app) for monitoring transplant phases for pediatric population

ERN-EuroBloodNet

 SATISFY Trial: Associating PROMs for PKD in Clinical Trial in Danish Red Blood Cell centers



European Rare Disease Research Coordination and Support Action

How patient advocates can contribute?



 Submit your PROMs of interest to be implemented in the repository (Survey available in June 2023)

Annotate your disease

- What: To document the functional consequences of rd on daily life
- How: 1 hour semi-structured interviews using the Orphanet Disability Thesarus (adapted from the WHO ICF)
- Who: Please contact Gavin McDonough at <u>disability.orphanet@inserm.fr</u>
- Why:
 - To build upon the knowledge of clinicians & patient associations
 - To increase the number of rd/clinical entities indexed online
 - To strengthen our on-going ERICA WP3 clustering work



Rare diseases clustering work



➔ A rare disease among your disease's cluster could have a questionnaire of interest for you



THANK YOU !



Céline Desvignes-Gleizes

Patient-Centred Outcomes specialist @: celine.desvignesgleizes@mapi-trust.org





Mariangela Pellegrini, Educational and patients project manager @: mariangela.pellegrini @aphp.fr



Gavin McDonough Disability/Handicap Project Manager

@: gavin.mcdonough@inserm.fr



Development PROM Performance of Upper Limb

ouchenne

arent

EURORDIS Masterclass 2023 Elizabeth Vroom, World Duchenne Organization

Development PROM starting from the patients

About the role of a patient organisation in PROM development

ouchenze



Outcome measures in DMD

ouchenze

ent.

6 minute walk test

Fast majority of DMD patients is non ambulant

Need of outcome measures for non ambulant patients

'Walking is highly overrated'

Interviewed patients

Common denominator

Being able to put your arms on the table

Use computer, brush your teeth

Starting point to develop PUL

and PUL - PROM

ouchenze

Arent

Performance Upper Limb

Working group formed

Funded by Patient Organisation

ouchenze

Arent

PUL functional outcome measure

PROM-PUL

Validated

Owned by Patient Organization



AIM

To develop a patient-reported outcome measure (PROM) assessing upper limb function related to activities of daily living (ADL) that cannot be observed in a clinical setting, specifically for patients with Duchenne muscular dystrophy (DMD) across a wide age range, applicable in the different stages of the disease.

oucher

METHOD

The developmental process was based on US Food and Drug Administration guidelines.

oucherry.

This included item generation from a systematic review of existing tools and expert opinion on task difficulty and relevance, involving individuals with DMD.

Cultural aspects affecting ADL were taken into consideration to make this tool applicable to the broad DMD community.

Items were selected in relation to a conceptual framework reflecting disease progression covering the full range of upper limb function across different ADL domains.


RESULTS

After pilot testing and iterative Rasch analyses, redundant or clinically irrelevant items were removed.

The final questionnaire consists of 32 items covering four domains of ADL (food, self-care, household and environment, leisure and communication).

Test-retest reliability was excellent.

INTERPRETATION

A DMD-specific upper limb PROM was developed on the basis of clinical relevance and psychometric robustness. Its main purpose is to document the patient selfreported natural history of DMD and assess the efficacy of interventions.

ouchen

Dev Med Child Neurol. 2013 Nov;55(11):1038-45. Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy

oucher

Mayhew A1, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, Vandenhauwe M, Klingels K, Florence J, Main M, Bianco F, Henrikson E, Servais L, Campion G, Vroom E, Ricotti V, Goemans N, McDonald C, Mercuri E; Performance of the Upper Limb Working Group. Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM

oucher

Klingels K, Mayhew AG, Mazzone ES, Duong T, Decostre V, Werlauff U, **Vroom** E, Mercuri E, Goemans NM; Upper Limb Clinical Outcome Group. Dev Med Child Neurol. 2016 Sep 26 Development of a conceptual framework reflecting the disease progression and functional decline in DMD with input from a broad array of stakeholders

Systematic and critical review of the existing questionnaires that include items related to upper limb function

Selection and adaptation of existing items and integration of newly constructed items based on input from experts, patients, and families

Involvement of male children and adults with DMD and their families in an iterative process to establish the clinical meaningfulness and relevance of items to activities of daily living and validate the conceptual framework

Development of a pilot pro forma with a first selection of items suitable for ambulant and non-ambulant young males with DMD

Application of the questionnaire in a multi-centre setting and consecutive Rasch analyses

Discussion with experts, patients, and families to interpret the results of the Rasch analyses followed by adaptations of the questionnaire

Development of the final questionnaire



A new patient-reported outcome measure (PROM) for Duchenne muscular dystrophy (DMD) has been developed.

ouchen

The DMD Upper Limb PROM targets upper limb function in daily life.

Psychometric techniques confirmed its unidimensionality, internal consistency, and test–retest reliability.

Involvement of different stakeholders guaranteed the clinical relevance of the tool.



ouchenne

Arent

Paper will be submitted shortly

Guidelines for the Translation of the 'DMD Upper Limb Patient Reported Outcome Measure'

ouchen

Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation

Translation



Ther Innov Regul Science. 2022 Jul;56(4):572-586. Unmet Therapeutic Needs of Non-Ambulatory Patients with Duchenne Muscular Dystrophy: A Mixed-Method Analysis

Anne L R Schuster 1, Norah L Crossnohere 2, Ryan Fischer 3, Patricia Furlong 3, John F P Bridges 2

Non-ambulatory Duchenne patients want new treatments that improve upper limb functioning and body system functioning, and not exclusively regaining ambulation. The PUL-PROM can be used as a patient-centric measure that accounts for the needs of later-stage Duchenne patients.



ouchenne

Patient Reported Outcome Measures



Standardisation

Validation

- Translation
- Qualification
- Trademark
- Licensing

Summary

Start from the patients perspective

Ability of Patient Organisation is relevant

ouchenze

Multistakeholder activity

C0-creation

Summary

Start from the patients perspective

Ability of Patient Organisation is relevant

ouchenze

Multistakeholder activity

C0-creation

Summary

Start from the patients perspective

Ability of Patient Organisation is relevant

ouchenze

Multistakeholder activity

Co-creation

